文献速递淋巴瘤

滤泡性淋巴瘤的组织学转化能否被预测和预防?

Can histologic transformation of follicular lymphoma be predicted and prevented?
PubMed 文献 · Blood · 2017-04-13

本文综述了临床、病理和遗传风险因素对滤泡性淋巴瘤组织学转化的预测价值,指出现有预后指数尚不能特异性地预测转化而非疾病进展或总生存;液体活检检测循环肿瘤DNA可能更好地反映瘤内异质性,并评估了基于治疗选择预防转化的文献证据。

要点

  • 多个临床高危因素并存的患者转化风险升高,但目前缺乏专门针对转化的预后指数。
  • 单个生物标志物与转化相关,但受限于对转化演化通路认识不足及大规模综合研究稀缺,准确预测仍困难。
  • 循环肿瘤DNA检测可能比单部位活检更好地反映瘤内异质性,助力精准医学。

核心结论

  • 可靠预测滤泡性淋巴瘤组织学转化目前仍是挑战,现有预后指数尚不能特异性预测转化而非疾病进展或总生存。
  • 液体活检检测循环肿瘤DNA可能比单部位活检更好地反映瘤内异质性,有望助力精准医学。
  • 文献中关于基于治疗选择能否预防转化的证据有待评估。

研究设计与样本

  • 综述,回顾临床、病理和遗传风险因素对滤泡性淋巴瘤组织学转化的预测价值,并评估预防转化的文献证据。

主要发现

  • 多个临床高危因素并存的患者转化风险升高,但目前缺乏专门针对转化的预后指数。
  • 多项研究将单个生物标志物与转化相关联,但准确预测受限于对转化演化通路认识不足及大规模综合研究稀缺。
  • 循环肿瘤DNA中检测到的突变可能比单部位活检更好地反映瘤内异质性。

临床怎么用

  • 理解转化风险有助于指导和监测患者,并评估可能预防转化的新治疗策略。

局限性

  • 目前缺乏专门针对转化而非疾病进展或总生存的预后指数。
  • 对导致转化的演化通路认识有限,且缺乏评估肿瘤细胞基因组改变与微环境组成的全面、大规模研究,阻碍了准确预测。
  • 文献中关于基于治疗选择能否预防转化的证据有待评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Transformation to aggressive lymphoma is a critical event in the clinical course of follicular lymphoma (FL) patients. Yet, it is a challenge to reliably predict transformation at the time of diagnosis. Understanding the risk of transformation would be useful for guiding and monitoring patients, as well as for evaluating novel treatment strategies that could potentially prevent transformation. Herein, we review the contribution of clinical, pathological, and genetic risk factors to transformation. Patients with multiple clinical high-risk factors are at elevated risk of transformation but we are currently lacking a prognostic index that would specifically address transformation rather than disease progression or overall survival. From the biological standpoint, multiple studies have correlated individual biomarkers with transformation. However, accurate prediction of this event is currently hampered by our limited knowledge of the evolutionary pathways leading to transformation, as well as the scarcity of comprehensive, large-scale studies that assess both the genomic landscape of alterations within tumor cells and the composition of the microenvironment. Liquid biopsies hold great promise for achieving precision medicine. Indeed, mutations detected within circulating tumor DNA may be a better reflection of the inherent intratumoral heterogeneity than the biopsy of a single site. Last, we will assess whether evidence exists in the literature that transformation might be prevented altogether, based on the choice of therapy for FL.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Kridel R, Sehn LH, Gascoyne RD, et al. Can histologic transformation of follicular lymphoma be predicted and prevented? Blood. 2017. PMID: 28408460. doi:10.1182/blood-2017-03-691345

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。